Castro-Rojas, Cyd M <br/><br/>
mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28- Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection.  [electronic resource] 

 -  Transplantation  05 2020 
 - 1058-1069 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1534-6080 
<br/><br/><label>Standard No.: </label>10.1097/TP.0000000000002917  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept--pharmacology<br/>Biopsy<br/>CD28 Antigens--immunology<br/>CD8-Positive T-Lymphocytes--immunology<br/>Female<br/>Graft Rejection--drug therapy<br/>Graft Survival<br/>Humans<br/>Immunologic Memory--drug effects<br/>Immunosuppression Therapy--methods<br/>Immunosuppressive Agents--pharmacology<br/>Kidney--pathology<br/>Kidney Transplantation<br/>Male<br/>Middle Aged<br/>Sirolimus--pharmacology<br/>T-Lymphocytes, Regulatory--drug effects<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Tacrolimus--pharmacology<br/>Transplantation, Homologous<br/>Treatment Outcome